Clinical trial NCT06475404: A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
Official title: Open-label Multi-cohort Study of the Tolerability, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers After a Single Intravenous Injection in Increasing Doses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Mucopolysaccharidosis Type II
Metabolic Diseases
Keywords: Mucopolysaccharidosis type II
Mucopolysaccharidoses
Metabolic Diseases
Lysosomal Storage Diseases
Carbohydrate Metabolism
Inborn
Metabolism
Genetic Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Genetic Diseases, X-Linked
Lead sponsor: AO GENERIUM
Sponsor class: INDUSTRY
First posted: 2024-06-26
Enrollment: 18
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: OTHER

Brief summary: It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers

Detailed description: GNR-055 (verenafusp alfa) is intended for enzyme replacement therapy (ERT) in patient with Mucopolysaccharidosis type II (MPS II), or Hunter syndrome. MPS II is a lysosomal storage disease with an X-linked recessive inheritance type, which is characterized by a decrease in the activity of the lysosomal enzyme iduronate-2-sulfatase (I2S), caused by a mutation in the idursulfase (IDS) gene. Enzyme deficiency leads to the accumulation of glycosaminoglycans (GAG) in lysosomes, mainly fractions of heparan and dermatan sulfates. Because of the insufficient activity of iduronate sulfatase participating in the first stage of catabolism of GAG, they accumulate in lysosomes of almost all types of cells of various tissues and organs. The disease is manifested by growth retardation, damage of many organs and systems, severe deformations of bones and joints, gross facial features, pathology of the respiratory and cardiovascular systems, damage to parenchymal organs (hepatosplenomegaly), hearing impairment. A severe form of the disease occurs with the involvement of the nervous system in the pathological process, including mental retardation, behavior anomalies, and impaired motor function.

GNR 055 (verenafusp alfa) is a modified enzyme I2S capable of penetrating the blood-brain barrier and thus it is expected to prevent neurodegenerative consequences and the development of cognitive deficit in the future that will allow achieving a significant improvement in the life quality and expectancy of patients with MPS II.

Eligibility criteria: Inclusion Criteria:

* Men aged 18 to 45 years (inclusive) at the time of signing the Informed Consent Form;
* Body mass index (BMI) 18.5 to 29.9 kg/m2, body weight of 50 to 90 kg;
* A verified diagnosis as "healthy" (the diagnosis "healthy" is established based on a detailed medical history, in the absence of deviations from normal values during a clinical examination, including measurement of blood pressure, respiratory rate, heart rate, body temperature, laboratory and instrumental (ECG) examination data);
* A written informed consent to participate in the study in accordance with applicable laws in place and compliance with all the procedures and requirements/restrictions provided for by the study protocol;
* Consent to use adequate methods of contraception (double barrier method-male or female (for partners of male research volunteers), condom with spermicide, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, cervical cap with spermicide).

Exclusion Criteria:

* Known hypersensitivity to idursulfase and/or to the medicinal product excipients;
* Burdened allergy history;
* Drug intolerance;
* History of seizures;
* Deposit injections or implants use of any other medicinal product three months before the Screening Visit;
* An unusual way of living (night working, extreme physical activity);
* Diarrhea dehydration, vomiting, or other causes within 24 hours before the Screening Visit;
* Deviations from the normal values of the clinical, laboratory, and ECG examinations;
* If there are acute or chronic diseases of the cardiovascular, bronchopulmonary, nervous, immune, and endocrine systems, diseases of the gastrointestinal tract, liver and biliary tract, kidney and urinary tract, blood and lymphatic system, a history of mental illness;
* Positive results for hepatitis B or C markers, human immunodeficiency virus (HIV), and syphilis;
* Acute infectious diseases less than four weeks before the Screening Visit;
* Regular administration of medicinal products less than two weeks before the Screening Visit;
* Systolic blood pressure (SBP) below 90 mm Hg or above 139 mm Hg; diastolic blood pressure (DBP) below 50 mm Hg or above 89 mm Hg; heart rate (HR) below 60 bpm or above 90 bpm;
* Blood donation (450 mL or more of blood or plasma) less than three months before the Screening Visit;
* Participation in human clinical studies of medicinal products less than three months before the Screening Visit;
* Consumption of more than 5 units of alcohol per week (1 unit of alcohol is equal to 30 ml of ethyl alcohol) OR history of alcoholism, drug addiction, or drug abuse;
* Alcohol exhale positive test;
* Drug addiction and positive urine analysis for potent and narcotic substances;
* Smoking more than 5 cigarettes per day;
* Any planned surgical intervention during the study period;
* Reluctance to comply with contraceptive methods;
* Vaccination (with any vaccine) within 30 days before signing the informed consent and/or the need for vaccination during the study period; 23. History of an autoimmune disease; 24. History of any cancer.

Primary outcomes:
measure: Proportion of participants with Adverse Events
timeFrame: Day 28
Secondary outcomes:
measure: Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)
timeFrame: Day 4
measure: Pharmacokinetics: Peak Plasma Concentration (Cmax)
timeFrame: Day 4
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department"
Study officials:
affiliation: JSC GENERIUM
name: Oksana A. Markova, MD
role: STUDY_CHAIR
References: